» Articles » PMID: 37451370

Oxidative Stress and Inflammation Are Mediated Via Aryl Hydrocarbon Receptor Signalling in Idiopathic Membranous Nephropathy

Overview
Date 2023 Jul 14
PMID 37451370
Authors
Affiliations
Soon will be listed here.
Abstract

Membranous nephropathy (MN) patients are diagnosed by the presence of phospholipase A receptor (PLA2R) before they progress to renal failure. However, the subepithelium-like immunocomplex deposit-mediated downstream molecular pathways are poorly understood. The aryl hydrocarbon receptor (AHR), NF-ƙB and Nrf2 pathways play central roles in the pathogenesis and progression of chronic kidney disease. However, their mutual effects on MN require further examination. Thus, we investigated the effect of AHR signalling on the NF-ƙB and Nrf2 pathways in IMN patients, cationic bovine serum albumin (CBSA)-injected rats and zymosan activation serum (ZAS)-treated podocytes. IMN patients show significantly decreased serum total protein and albumin levels, increased urine protein levels and intrarenal IgG and PLA2R protein expression in glomeruli compared with controls. IMN patients exhibited increased mRNA expression of intrarenal AHR and its target genes, including CYP1A1, CYP1A2, CYP1B1 and COX-2. This increase was accompanied by significantly upregulated protein expression of CD3, NF-ƙB p65 and COX-2 and significantly downregulated Nrf2 and HO-1 expression. Similarly, CBSA-induced rats showed severe proteinuria and activated intrarenal AHR signalling. This was accompanied by significantly upregulated protein expression of intrarenal p-IκBα, NF-κB p65 and its gene products, including COX-2, MCP-1, iNOS, 12-LOX, p47 and p67, and significantly downregulated protein expression of Nrf2 and its gene products, including HO-1, catalase, GCLC, GCLM, MnSOD and NQO1. These results were further verified in ZAS-induced podocytes. Treatment with the AHR antagonist CH223191 and AHRsiRNA significantly preserved podocyte-specific protein expression and improved the NF-ƙB and Nrf2 pathways in ZAS-induced podocytes. In contrast, similar results were obtained in ZAS-induced podocytes treated with the NF-ƙB inhibitor BAY 11-7082 and NF-κBp65 siRNA. However, neither method had a significant effect on AHR signalling. Collectively, these results indicate that the NF-ƙB pathway is a downstream target of AHR signalling. Our findings suggest that blocking AHR signalling inhibits oxidative stress and inflammation, thereby improving proteinuria and renal injury.

Citing Articles

Focus on podocytes: diabetic kidney disease and renal fibrosis - a global bibliometric analysis (2000-2024).

An D, Tan J, Lu Y, Wen Z, Bao Y, Yao Z Front Pharmacol. 2024; 15:1454586.

PMID: 39619610 PMC: 11605685. DOI: 10.3389/fphar.2024.1454586.


Oxidative Imbalance in Psoriasis with an Emphasis on Psoriatic Arthritis: Therapeutic Antioxidant Targets.

Bilski R, Kupczyk D, Wozniak A Molecules. 2024; 29(22).

PMID: 39598849 PMC: 11597651. DOI: 10.3390/molecules29225460.


Barleriside A, an aryl hydrocarbon receptor antagonist, ameliorates podocyte injury through inhibiting oxidative stress and inflammation.

Li X, Wang Y, Wang W, Nie X, Miao H, Zhao Y Front Pharmacol. 2024; 15:1386604.

PMID: 39239643 PMC: 11374728. DOI: 10.3389/fphar.2024.1386604.


Bioenergetic and Inflammatory Alterations in Regressed and Non-Regressed Patients with Autism Spectrum Disorder.

Gevezova M, Ivanov Z, Pacheva I, Timova E, Kazakova M, Kovacheva E Int J Mol Sci. 2024; 25(15).

PMID: 39125780 PMC: 11311370. DOI: 10.3390/ijms25158211.


Astragaloside IV relieves passive heymann nephritis and podocyte injury by suppressing the TRAF6/NF-κb axis.

Ma Y, Hu Y, Ruan Y, Jiang X, Zhao M, Wang Y Ren Fail. 2024; 46(2):2371992.

PMID: 39082739 PMC: 11293271. DOI: 10.1080/0886022X.2024.2371992.